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OBJECTIVE — A1Chasbeenproposedasanewindicatorforhighriskoftype2diabetes.The
long-termpredictivepowerandcomparabilityofelevatedA1Cwiththecurrentlyusedhigh-risk
indicators remain unclear. We assessed A1C, impaired glucose tolerance (IGT), and impaired
fasting glucose (IFG) as predictors of type 2 diabetes and cardiovascular disease (CVD) at 10
years.
RESEARCH DESIGN AND METHODS — This prospective population-based study of
593 inhabitants from northern Finland, born in 1935, was conducted between 1996 and 2008.
An oral glucose tolerance test (OGTT) was conducted at baseline and follow-up, and A1C was
determined at baseline. Those with a history of diabetes were excluded from the study. Elevated
A1C was deﬁned as 5.7–6.4%. Incident type 2 diabetes was conﬁrmed by two OGTTs. Cardio-
vascular outcome was measured as incident CVD or CVD mortality. Multivariate log-binomial
regression models were used to predict diabetes, CVD, and CVD mortality at 10 years. Receiver
operating characteristic curves compared predictive values of A1C, IGT, and IFG.
RESULTS — Incidence of diabetes during the follow-up was 17.1%. Two of three of the cases
of newly diagnosed diabetes were predicted by a raise in 1 of the markers. Elevated A1C, IGT,
or IFG preceded diabetes in 32.8, 40.6, and 21.9%, respectively. CVD was predicted by an
intermediate and diabetic range of 2-h glucose but only by diabetic A1C levels in women.
CONCLUSIONS — A1C predicted 10-year risk of type 2 diabetes at a range of A1C 5.7–
6.4% but CVD only in women at A1C 6.5%.
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E
arly detection of high risk for type 2
diabetes is fundamental for preven-
tion of diabetes and associated car-
diovascular complications. Impaired
fasting glucose (IFG) and impaired glu-
cose tolerance (IGT) are currently used
for diagnosis of high-risk glucose levels
below the diabetic range. The Interna-
tional Expert Committee proposed A1C
6.5% as a diagnostic tool for diabetes in
2009(1)andinJanuary2010aninterme-
diate range of A1C 5.7–6.4% (elevated
A1C) was proposed by the American Di-
abetes Association (ADA) to detect indi-
viduals at high risk for developing type 2
diabetes (2).
To date, however, limited data exist
to support the use of A1C in predicting
type 2 diabetes (3–8). Importantly, the
long-term predictive power of elevated
A1C as deﬁned above has not yet been
investigated. Previous data on the associ-
ation between A1C and incident type 2
diabetes in unselected populations have
relied on self-reporting, fasting glucose
measurements, and use of antidiabetes
medication to determine the outcomes.
Anoralglucosetolerancetest(OGTT)has
not been used to determine the outcome
(3–8).
Deterioration of glucose homeostasis
reﬂects a continuum of glycemia, some of
which is reversible if detected early
(9,10).Importantly,theriskofcardiovas-
cular disease is increased already before
glycemia reaches the levels of diabetes,
and 2-h glucose appears to be a better
predictorofcardiovasculardisease(CVD)
than fasting glucose (11). Recently, A1C
wasshowntobeabetterpredictorofCVD
than fasting glucose (12).
Data directly comparing 2-h glucose
and A1C as long-term predictors of new-
onset cardiovascular disease are scarce,
and results are controversial (13,14).
Therefore, we compared A1C, 2-h glu-
cose, and fasting glucose as predictors of
type 2 diabetes, CVD, and CVD mortality
during a prospective population-based
study with a 10-year follow-up.
RESEARCH DESIGN AND
METHODS— This study conducted
in 1996–2008 is part of a longer fol-
low-up study assessing type 2 diabetes
andIGT,inwhichallinhabitantsofcityof
Oulu, Finland, born in 1935 were invited
to participate. Between 1996 and 1998,
831 were invited, of whom 593 (245
men) enrolled. Formation of the study
population is shown in Fig. 1. Recruit-
ment process and methods have been de-
scribed previously (15). Type 2 diabetes
wasconﬁrmedbytwodiabetic2-hand/or
fasting values. There were no signiﬁcant
differences in sex, baseline glucose status,
anthropometric measurements, blood
pressure, or lipid proﬁle between the par-
ticipants and nonparticipants. A higher
prevalence of current smoking was ob-
served among nonparticipants (28.9 vs.
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Procedures
A standardized 75-g OGTT was per-
formed in 1996–1998 and 2007–2008.
After a 12-h overnight fast, venous blood
samples were drawn between 8:00 and
10:00 AM for fasting glucose and also for
A1C at baseline. After ingestion of a 75-g
liquid glucose load, a blood sample was
drawn for 2-h glucose. At baseline, the
fasting value was determined from whole
blood and 2-h glucose was determined
from a capillary sample in accordance
with contemporary guidelines (16). Cap-
illary samples were analyzed immediately
after collection. At follow-up, venous
plasma, drawn in containers with glyco-
lytic inhibitors and centrifuged immedi-
ately to separate plasma, according to the
World Health Organization (WHO) 2006
recommendations (17), was used for both
glucose measurements. Glucose concentra-
tion was determined using the hexokinase-
glucose-6-phosphate dehydrogenase
method. A1C was analyzed with a Bayer
DCA2000 analyzer, calibrated to the Dia-
betes Control and Complications Trial
standard (18).
Clinical examination was conducted
by a trained research nurse. Height (cen-
timeters) and weight (kilograms) were
measured with the individual in light
Figure 1—Formation of the study population for diabetes and CVD analysis.
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divided by the square of height in meters)
was calculated. Participants completed
questionnaires on smoking, alcohol con-
sumption, and exercise. Smoking was
quantiﬁed (number of cigarettes and
years smoked), and smoking status was
classiﬁed into current or nonsmokers. Al-
cohol consumption was quantiﬁed (units
per week), and alcohol status was classi-
ﬁed as abstainer or user. Exercise behav-
iorwasdeterminedbyaskingparticipants
about the frequency and duration of ex-
ercise and was classiﬁed as active or inac-
tive, as described elsewhere (19).
Cardiovascular and mortality
outcomes
Incidence of CVD and CVD mortality was
evaluatedfromdateofthebaselineOGTT
in1996–1998to1May2009.Cardiovas-
cular diagnoses (coded according to ICD-
10: I00–I99) were obtained from the
Oulu University Hospital discharge regis-
ter for inpatient and outpatient visits. The
prevalence of CVD was self-reported by
participants at baseline. All participants
live in the catchment area of the same ter-
tiary care center, and any cardiovascular
symptoms requiring hospital care were
thustreatedinthesamecenter.Information
on deaths was obtained from ofﬁcial death
certiﬁcates (obtained from Statistics, Fin-
land), coded according to ICD-10.
Statistical analysis
Glucosetolerancestatuswasclassiﬁedac-
cording to the WHO 1999 criteria (16).
Because of the low number of individuals
with combined IFG and IGT, this group
was included in the IGT group for analy-
sis.Baselinecharacteristicsofgroupswere
compared with t tests and the Mann-
Whitney U test, where appropriate. Cate-
gorical variables, presented as percentages,
were compared with a 
2 test. Associa-
tions between fasting and 2-h glucose,
A1C and incident type 2 diabetes, and
CVD were analyzed with log-binomial re-
gression. Crude and adjusted relative
risks with 95% CI are presented. Predic-
tive properties of fasting and 2-h glucose
andA1Cforincidenttype2diabeteswere
evaluated with receiver operating charac-
teristic curves. Areas under the receiver
operating characteristic curves (AUCs)
were calculated and compared with a
nonparametric method (20). All data
were analyzed with Stata (version 11MP).
RESULTS— Breakdown of glucose
tolerance status of the cohort at baseline
was 74.1, 18.7, 7.2, and 2.7% for normal
glucose tolerance, IGT, IFG, and com-
bined IGT and IFG, respectively. During
the follow-up (mean  SD time of 9.7 
0.7 years), incidence of type 2 diabetes
was 17.1% (n  64).
Characteristics of the cohort at base-
line and follow-up are shown (Table 1).
Participants who developed type 2 diabe-
tes had higher fasting glucose, 2-h glu-
cose, and A1C at baseline (P  0.0001)
and higher BMI at baseline (P  0.0005)
compared with those who remained
nondiabetic.
The proportion of individuals who
developed diabetes during the follow-up
was similar in all groups (37.8% of sub-
jects with IFG, 37.1% with IGT, and
37.5% with elevated A1C, respectively).
Crude risk ratios (RRs) of risk of diabetes
were relatively similar for IFG (RR 2.56
[95% CI 1.57–4.16]), IGT (2.98 [1.94–
4.56]), and elevated A1C (2.78 [1.80–
4.31]). When adjusted for sex, BMI at
baseline, smoking, alcohol, and exercise,
corresponding RRs were 2.37 [1.49–
3.78], 2.90 [1.90–4.43], and 2.42
[1.50–3.91] for IFG, IGT, and A1C,
respectively.
Breakdown of type 2 diabetes as pre-
dicted by the three tests is illustrated in
Fig. 2. In total, 65.7% of the cases of
newly diagnosed diabetes were predicted
by a raise in 1 markers at baseline. The
most common condition to precede dia-
betes was IGT (40.6%), followed by ele-
vated A1C (32.8%), followed by IFG
(21.9%). An elevation in an isolated
marker predicted type 2 diabetes in a re-
markable number of subjects. Percent-
ages of isolated IGT, isolated elevated
A1C, and isolated IFG preceding diabetes
were 23.4, 14.1% and 6.3%, respectively
(P  0.31). A relatively small percentage
of cases of diabetes were preceded by a
combination of two markers, with all
three elevated in only 7.8% of partici-
pantswhodevelopeddiabetes.Speciﬁcity
of IGT, IFG, and A1C for incident type 2
diabetes was 85.9–92.6% (Fig. 3). AUC
ranged from 0.69 for 2-h glucose to 0.61
forfastingglucose(P0.36forequality).
Total incidence of new CVD was
37.6% and according to sex, 34.3% in
women and 42.7% in men. In women,
32% with A1C 5.7–6.4 and 100% with
A1C 6.5% developed CVD (RR 0.96
[95% CI 0.62–1.49] and 2.99 [2.50–
Table 1—Characteristics of the cohort by sex at baseline (1996–1998) and at follow-up
(2007–2008)
Men Women P value
Baseline
n 223 330
Screen detected type 2 diabetes (%) 10.3 08.5 0.4659
BMI (kg/m
2) 27.6  3.5 27.9  4.5 0.4492
Current smokers (%) 18.4 14.9 0.2773
Alcohol use (%) 84.3 70.0 0.0001
Physically inactive (%) 28.2 23.7 0.2432
Diastolic blood pressure (mmHg) 79.5  7.6 78.8  7.6 0.3875
Systolic blood pressure (mmHg) 141.8  17.7 141.5  16.7 0.8587
Total cholesterol (mmol/l) 5.6  0.9 6.0  0.9 0.001
HDL cholesterol (mmol/l) 1.3  0.3 1.6  0.4 0.001
LDL cholesterol (mmol/l) 3.7  0.8 3.8  0.8 0.0902
Fasting glucose (mmol/l) 5.0  0.6 5.0  0.6 0.1884
2-h glucose (mmol/l) 6.8  2.1 7.0  1.7 0.0173
A1C (%) 5.4  0.4 5.4  0.4 0.6721
Self-reported previous CVD (%) 8.5 5.5 0.1570
Follow-up (%)
New CVD diagnosis 45.3 35.8 0.0245
All-cause mortality 10.8 07.6 0.1958
CVD mortality 04.3 01.9 0.1101
Glucose status (%) 0.001
n 168 258
Type 2 diabetes 26.2 19.0
IGT 20.8 19.4
IFG 16.1 07.0
Normal glucose tolerance 36.9 54.6
Data are means  SD or %.
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glucose was signiﬁcantly associated with
incident CVD in the IGT range (47.5%
incidence; 1.65 [1.19–2.30]) and dia-
betic range (58.3% incidence; 2.03
[1.21–3.41]). Risk of incident CVD in
women with IGT, a diabetic range of 2-h
glucose, and diabetic A1C remained sig-
niﬁcant even after adjustment for BMI,
smoking, blood pressure, LDL, HDL, and
family history of diabetes (1.72 [1.24–
2.38], 2.03 [1.21–3.41], and 2.85 [1.96–
4.12], respectively). Mortality from CVD
was low (n  15, of which 9 were men);
thus, subgroup analysis did not reach sta-
tistical signiﬁcance.
CONCLUSIONS — We compared
A1C, a recently proposed indicator for
high risk of diabetes, with the currently
used2-handfastingglucoseaspredictors
of incident type 2 diabetes and CVD dur-
ing10years.Toourknowledge,thisisthe
ﬁrst study comparing the recently pro-
posed range of elevated A1C (5.7–6.4%)
with both 2-h and fasting glucose, mea-
suring the outcome with an OGTT. Fur-
thermore, data comparing A1C and 2-h
glucose regarding future cardiovascular
risk are scarce and have been focused on
mortality and yielded controversial re-
sults. Here, we examined outcome of in-
dividuals with new CVD presenting to a
tertiary care center, thereby adding im-
portant evidence to the use of A1C as a
predictor of incident macrovascular com-
plications in those without a history of
diabetes.
Different markers detected different
individuals at risk of diabetes. Impor-
tantly, a marked amount of diabetes was
preceded by elevation in one of the glyce-
mic markers only, with limited overlap
among the three. Fasting and 2-h glucose
reﬂect different pathophysiological
mechanisms of abnormal glucose ho-
meostasis (21,22). The pathophysiology
of isolated IFG includes reduced hepatic
insulin sensitivity, -cell dysfunction,
and reduced -cell mass (23). With iso-
lated IGT, peripheral insulin sensitivity is
reduced with a near-normal hepatic insu-
lin sensitivity and progressive loss of
-cell function (23). In contrast with
acute-phase markers, A1C is a widely
used marker of chronic glycemia, reﬂect-
ing average blood glucose levels over 2–3
months.
Ourresultslendsupporttotherecent
suggestion that an intermediate range of
Figure 2—Venn diagram representing the percentage of elevated A1C, IGT, and IFG at baseline among participants who developed diabetes during
the 10-year follow-up (n  64). Area outside the circles indicates those with no elevated markers at baseline. Percentages in brackets indicate
participants with either an isolated marker or a combination of markers. Surface area of region is proportional to the percentage.
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abetes (2), particularly if combined with
fasting glucose (3,7). The range of A1C
usedinpreviousstudiesassessingtherisk
offuturediabeteshasvaried,andelevated
risk has been shown in ranges between
5.5 and 6.5% (6,8). A1C of 5.6–6.4%
carried a hazard ratio of 13.7 for use of
antidiabetes drug treatment at 3 years in
Japanese (8), lending support to our ﬁnd-
ings in a similar range, but with a mark-
edlylongerfollow-upperiodinourstudy.
To our knowledge, this is the ﬁrst longi-
tudinal study of the nondiabetic A1C
range and incident type 2 diabetes, as
measured by an OGTT, in which the re-
cently proposed A1C range of 5.7–6.4%
has been evaluated.
Here,A1C,IGT,andIFGwereallspe-
ciﬁc, but not sensitive, predictors of 10-
year risk of type 2 diabetes. The
proportionofparticipantswhodeveloped
diabeteswithIGT,elevatedA1C,andIFG
wasobservedtobesimilar,approximately
one-third.IGThadthehighestprevalence
in this population, and thus the actual
number of participants who developed
diabetes was greatest in the IGT group. It
has also been observed in the National
Health and Nutrition Examination Sur-
veys that the 2-h glucose value is more
sensitive for detecting impaired glucose
regulation and type 2 diabetes in elderly
individuals (24).
The ultimate importance of a predic-
tive test for type 2 diabetes is determined
byitsabilitytoindicatehighriskforCVD.
Risk of CVD is increased already before
glycemia reaches levels of diabetes, and
2-h glucose seems to be a better predictor
of CVD than fasting glucose (11).
Longitudinal data on cardiovascular
risk comparing 2-h glucose and A1C in
the nondiabetic range have been scarce,
and results are controversial. An associa-
tion was observed between 2-h glucose
and, to lesser extent, between A1C and
cardiovascular mortality in Dutch adults
(14), but in U.S. adults, A1C was a better
predictor of CVD than postchallenge glu-
cose in women without diabetes (13).
Cardiovascular mortality, however, is a
lateendpoint,andwethereforeexamined
the incidence of new-onset CVD. In our
study IGT was the only marker in the
nondiabetic range signiﬁcantly associated
with incident CVD in women. A1C was
signiﬁcantly associated with incident
CVD in women in the higher range of
6.5%.Toourknowledge,thisistheﬁrst
longitudinal report comparing elevated
A1C as deﬁned by the recently proposed
ADA criteria and 2-h glucose at a nondi-
abetic level as predictors of new-onset
CVD.
Hyperglycemia was a risk factor for
CVD in women but not in men, indepen-
dent of BMI, smoking, blood pressure,
lipids, and family history of diabetes in
thisage-standardizedcohort.Ourﬁnding
of CVD risk conveyed by hyperglycemia
in women but not in men is consistent
Figure3—ReceiveroperatingcharacteristiccurvesforIGT,elevatedA1C,andIFG.Sensitivity(Sens)andspeciﬁcity(Spec)werecalculatedforA1C
5.7% and lower limits of IFG and IGT. For 2-h glucose AUC  0.689, for A1C AUC  0.659, and for fasting glucose AUC  0.612. For differences
between AUCs, P  0.359. F, 2-h glucose; , A1C; ‚, fasting glucose.
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for it remains unclear (25).
Our study has several strengths. Di-
agnosis of CVD was conﬁrmed from ter-
tiary care hospital records. The broad
range of CVD included coronary heart
disease, ischemic stroke, carotid artery
disease, and peripheral vascular disease
(ICD-10 codes I00–I99). Incident diabe-
tes was a clinical diagnosis, conﬁrmed by
two results. We investigated the predic-
tive power of elevated A1C using the cri-
teria recently proposed by the ADA.
Findings from this study are, how-
ever, limited because of its aging Cauca-
sian population and generalizing them
must be done with caution. Baseline CVD
statuswasself-reported,andmilddegrees
of CVD cannot be excluded. We were un-
able to analyze CVD mortality in relation
to glycemic subgroups because of the low
numbers. Because samples for glucose
measurements were drawn in accordance
with the contemporary guidelines (WHO
1999 and WHO 2006, respectively)
(16,17), capillary samples were used for
2-h glucose at baseline, but plasma was
used at follow-up. It is recognized that
capillary samples in the nonfasting state
will give slightly higher results than ve-
nous samples (17), but the effect at the
population level, with values used only
for classiﬁcation of glucose status and not
measuring an absolute change in glucose,
is likely to be marginal.
In summary, A1C and 2-h glucose,
but not fasting glucose, were associated
with incident CVD in women, but not in
men. Among women with screen-
detected diabetes, both A1C and 2-h glu-
cose were signiﬁcant predictors of
incident diagnosis of CVD. Finally,
among nondiabetic women, 2-h glucose
was the only glycemic marker signiﬁ-
cantly associated with incident CVD.
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